Treatment of liver damage with SSAO inhibitors
The SSAO/VAP-1 inhibitor, Compound 1, addresses the lack of effective NASH treatments by providing low-dose, less frequent administration options that reduce liver inflammation and fibrosis with minimal side effects.
Patent Information
- Application Number
- JP2024527619
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-06-07
- Filing Date
- 2022-11-11
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for non-alcoholic steatohepatitis (NASH) are lacking, and existing therapies often require frequent administration and cause side effects, leading to low patient compliance, while there are no approved treatments available.
Administration of a semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) inhibitor, Compound 1, at low doses that achieve partial to full saturation of plasma SSAO, reducing lymphocyte adhesion and migration, and administered once daily or less frequently to maintain efficacy.
Compound 1 effectively reduces liver inflammation and fibrosis in NASH patients with minimal side effects, demonstrating long-term pharmacodynamic effects and steady-state plasma concentrations that support less frequent dosing.
Smart Images

Figure 2024543419000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 263,934, filed November 11, 2021, and No. 63 / 349,978, filed June 7, 2022. The contents of the aforementioned patent applications are hereby incorporated by reference in their entirety for all purposes.
[0002] The present invention relates to methods and compositions for treating liver disease, including non-alcoholic steatohepatitis (NASH), in a patient. [Background technology]
[0003] Fatty liver disease (FLD) encompasses a range of disease states characterized by excessive accumulation of fat in the liver, often accompanied by inflammation. FLD can lead to nonalcoholic fatty liver disease (NAFLD). If untreated, NAFLD can progress to persistent inflammatory responses or nonalcoholic steatohepatitis (NASH), progressive liver fibrosis, and ultimately cirrhosis. In the Western world, NAFLD is the second most common reason for liver transplantation. Thus, the need for treatment is urgent, but because patients lack obvious symptoms, they may lack motivation to maintain a treatment regimen, especially one that is burdensome, either involving injectable drugs, drugs administered multiple times a day, or that produce dangerous or irritating side effects. Currently, there is no approved treatment for NASH. Summary of the Invention
[0004] Provided herein are methods and compositions for treating liver damage, such as NASH, in a patient in need thereof, the method comprising administering to the patient a semicarbazide-sensitive amine oxidase (SSAO) / vascular adhesion protein-1 (VAP-1) inhibitor having the following structure (referred to herein as "Compound 1"), or a pharma- ceutical acceptable salt thereof. [ka] Compound 1 has the chemical name (E)-3-fluoro-2-(((2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl)oxy)methyl)prop-2-en-1-amine and is described in U.S. Patent Application Publication No. 2018 / 0297987, which is incorporated herein by reference in its entirety. In one form, Compound 1 is provided as the free base. In another form, Compound 1 is provided as an acid addition salt, such as a monohydrochloric acid addition salt or dihydrochloric acid addition salt(s), or a sulfonate salt, preferably 4-methylbenzenesulfonate salt (tosylate salt).
[0005] The present inventors have discovered that Compound 1 or a pharma- ceutically acceptable salt thereof can be administered to patients suffering from liver damage at surprisingly low doses while still maintaining a desirable level of efficacy. This discovery is based in part on the observation that Compound 1 has a very strong affinity for plasma SSAO, thereby exhibiting target-mediated saturable clearance. Compound 1 or a pharma- ceutically acceptable salt thereof can be administered at a dose that is either completely saturated with plasma SSAO or less than completely saturated with plasma SSAO. Plasma SSAO is an active soluble plasma SSAO that is released into plasma by membrane-bound plasma SSAO. As described herein, Compound 1 or a pharma- ceutically acceptable salt thereof can be administered at a dose that is less than completely saturated with plasma SSAO and still be effective. In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof can be administered at a dose that achieves at least about 25% saturation of plasma SSAO targets. In another embodiment, Compound 1 or a pharma- ceutically acceptable salt thereof can be administered at a dose that achieves at least about 50% saturation of plasma SSAO targets. In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof may be administered at a dose that achieves at least about 75% saturation of plasma SSAO targets.In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof may be administered at a dose that achieves at least about 95% saturation of plasma SSAO targets.In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof may be administered at a dose that achieves at least about 100% saturation of plasma SSAO targets.
[0006] In some embodiments of the present disclosure, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient at a low dose of 1 mg or less once a day and still be able to sufficiently reduce amine oxidase activity and reduce lymphocyte adhesion and migration. For example, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 0.5 mg to about 25 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 1 mg to about 15 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 2 mg to about 10 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 1 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 4 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 5 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 10 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 20 mg once a day.
[0007] Furthermore, the present inventors have surprisingly discovered that compound 1 has a long-lasting pharmacodynamic effect that supports even less than once-a-day administration to patients suffering from liver damage (e.g., NASH). For example, compound 1 or a pharmaceutically acceptable salt thereof can be administered once every other day (e.g., three or four times a week). In some embodiments, compound 1 or a pharmaceutically acceptable salt thereof can be administered once a week. In embodiments in which compound 1 or a pharmaceutically acceptable salt thereof is administered less than once a day, administration can be oral or parenteral (e.g., intramuscular, subcutaneous, or intravenous).
[0008] In some embodiments of the present disclosure, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose that provides a plasma methylamine concentration of at least 25 ng / mL when the plasma concentration of compound 1 reaches a steady state. In other embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose that provides a plasma methylamine concentration of at least about 50 ng / mL when the plasma concentration of compound 1 reaches a steady state. In other embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose that provides a plasma methylamine concentration of at least about 100 ng / mL when the plasma concentration of compound 1 reaches a steady state. In other embodiments, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose that provides a plasma methylamine concentration of at least about 100 ng / mL when the plasma concentration of compound 1 reaches a steady state. In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is at least about 200 ng / mL when the plasma concentration of compound 1 reaches a steady state. In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is at least about 300 ng / mL when the plasma concentration of compound 1 reaches a steady state. In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is at least about 300 ng / mL when the plasma concentration of compound 1 reaches a steady state. In another embodiment, compound 1 or a pharmaceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is at least about 25 ng / mL to about 400 ng / mL when the plasma concentration of compound 1 reaches a steady state.In another embodiment, Compound 1 or a pharma- ceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is about 50 ng / mL to about 350 ng / mL when the plasma concentration of Compound 1 reaches a steady state. In another embodiment, Compound 1 or a pharma-ceutically acceptable salt thereof is administered to a patient suffering from liver damage (e.g., NASH) at a dose such that the plasma methylamine concentration is about 100 ng / mL to about 300 ng / mL when the plasma concentration of Compound 1 reaches a steady state.
[0009] In one aspect, the disclosure provides a method of reducing liver inflammation in a patient in need thereof, comprising administering to the patient Compound 1, or a pharma- ceutically acceptable salt thereof, wherein Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in a dose described herein.
[0010] In another aspect, the disclosure provides a method of reducing liver fibrosis in a patient in need thereof, comprising administering Compound 1, or a pharma- ceutically acceptable salt thereof, to the patient, wherein Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in a dose described herein.
[0011] In another aspect, the disclosure provides a method of treating a disease or condition characterized by liver fibrosis comprising administering to a patient Compound 1, or a pharma- ceutically acceptable salt thereof, wherein Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in a dose described herein. [Brief description of the drawings]
[0012] [Figure 1A] 1 shows plasma SSAO-specific amine oxidase activity compared to baseline and 4 and 168 hours after administration of a single dose of placebo or 1, 3, 6, or 10 mg of Compound 1 in healthy volunteers. [Figure 1B]1 shows the time course of plasma total amine oxidase activity compared between baseline and a single dose of placebo or 1, 3, 6, or 10 mg of Compound 1 in healthy volunteers. [Figure 1C] 1 shows the time course of Compound 1 levels following single doses of placebo or 1, 3, 6, or 10 mg of Compound 1 in healthy volunteers. [Figure 1D] 1 shows the time course of plasma methylamine concentrations following single doses of placebo or 1, 3, 6, or 10 mg of Compound 1 in healthy volunteers.
[0013] [Figure 2A] 1 shows the time course of Compound 1 concentrations following single doses of 1, 4, or 10 mg of Compound 1 administered to healthy volunteers. [Figure 2B] The time course of Compound 1 concentration is shown for the final day of a 7-day administration of Compound 1 at a daily dose of 1 mg or 4 mg, and for the final day of a 14-day administration of Compound 1 at a daily dose of 10 mg.
[0014] [Figure 3A] SSAO-specific amine oxidase activity 24 hours after the first dose of Compound 1 at daily doses of 1, 4, or 10 mg is shown. [Figure 3B] 1 shows the time course of plasma methylamine concentrations following an initial daily dose of 1, 4, or 10 mg of Compound 1. [Figure 3C] 1 shows the time course of plasma methylamine concentrations after the final day of a 7-day treatment with Compound 1 at a daily dose of 1 mg or 4 mg, and after the final day of a 14-day treatment with Compound 1 at a daily dose of 10 mg. [Figure 3D] 1 shows the time course of total amine oxidase activity following single doses of 1, 4, or 10 mg of Compound 1 in healthy volunteers. [Figure 3E] 1 shows the 14-day time course of total amine oxidase activity following the 6th of a 7-day administration of 1 mg or 4 mg daily doses of Compound 1, or the 13th of a 14-day administration of a 10 mg daily dose of Compound 1 to healthy volunteers.
[0015] [Figure 4] The overall study design for Compound 1 is shown.
[0016] [Diagram 5] Patient demographics and baseline characteristics are shown.
[0017] [Figure 6] The distribution of patients according to study design is shown.
[0018] [Figure 7] A general overview of adverse events is provided.
[0019] [Figure 8A] TIMP-1 change from baseline to weeks 6 and 12 is shown.
[0020] [Figure 8B] Results are shown for mean (SE) change from baseline to week 12 in NASH and inflammatory biomarkers.
[0021] [Figure 9] cT1 changes at 12 weeks are shown.
[0022] [Figure 10] VAP-1 / SSAO activity (%) at week 12 compared to baseline is shown.
[0023] [Figure 11] Changes in ELF components (TIMP-1, P3NP, HA) from baseline to week 12 are shown.
[0024] [Figure 12] Changes in ICAM-1 and VCAM-1 from baseline to week 12 are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0025] definition As used herein, the following definitions shall apply unless otherwise indicated. Furthermore, if any term or symbol used herein is not defined as set forth below, it shall have the meaning it ordinarily has in the art.
[0026] "Comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude other elements. When used to define compositions and methods, "consisting essentially of" is intended to mean excluding other elements of any essential importance to the combination. For example, a composition consisting essentially of the elements defined herein does not exclude other elements that do not materially affect the basic and novel feature(s) of the claimed invention. "Consisting of" is intended to mean, for example, excluding more than trace amounts of other recited components and substantial method steps. Embodiments defined by each of these transitional phrases are within the scope of the invention.
[0027] The term "excipient" as used herein means an inert or inactive substance that may be used in the manufacture of a drug or pharmaceutical product, such as a tablet, that contains a compound of the present invention as an active ingredient. A variety of substances may be encompassed under the term excipient, including, but not limited to, any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, solution for parenteral administration, material for chewable tablets, sweetener or flavoring, suspending / gelling agent, or wet granulation agent. Binders include, for example, carbomer, povidone, xanthan gum, and the like; coatings include, for example, cellulose acetate phthalate, ethylcellulose, gellan gum, maltodextrin, enteric coatings, and the like; compression / encapsulation aids include, for example, calcium carbonate, dextrose, fructose dc (dc = "directly compressible"), honey dc, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, sucrose, and the like; disintegrants include, for example, croscarmellose sodium, gellan gum, sodium starch glycolate, and the like; creams or lotions include, for example, , maltodextrin, carrageenan, etc.; lubricants include, for example, magnesium stearate, stearic acid, sodium stearyl fumarate, etc.; chewable tablet materials include, for example, dextrose, fructose dc, lactose (monohydrate, optionally in combination with aspartame or cellulose), etc.; suspending / gelling agents include, for example, carrageenan, sodium starch glycolate, xanthan gum, etc.; sweeteners include, for example, aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; wet granulating agents include, for example, calcium carbonate, maltodextrin, microcrystalline cellulose, etc.
[0028] "Patient" refers to a mammal, including humans and non-human mammals. Examples of patients include, but are not limited to, mice, rats, hamsters, guinea pigs, pigs, rabbits, cats, dogs, goats, sheep, cows, and humans. In some embodiments, a patient refers to a human.
[0029] "Pharmaceutically acceptable" refers to safe and non-toxic, preferably for in vivo, and more preferably for administration to humans.
[0030] "Pharmaceutically acceptable salt" refers to a salt that is pharma- ceutically acceptable. The compounds described herein may be administered as a pharma- ceutically acceptable salt.
[0031] "Salt" refers to an ionic compound formed between an acid and a base. When the compounds provided herein contain an acidic functional group, such salts include, but are not limited to, alkali metal, alkaline earth metal, and ammonium salts. As used herein, ammonium salts encompass salts containing protonated nitrogen bases and alkylated nitrogen bases. Exemplary, non-limiting cations useful for pharmaceutically acceptable salts include Na, K, Rb, Cs, NH4, Ca, Ba, imidazolium, and ammonium cations based on naturally occurring amino acids. When the compounds used herein contain a basic functional group, such salts include, but are not limited to, salts of organic acids such as carboxylic and sulfonic acids, and mineral acids such as hydrogen halides, sulfuric acid, phosphoric acid, and the like. Exemplary, non-limiting anions useful for pharmaceutically acceptable salts include oxalate, maleate, acetate, propionate, succinate, tartrate, chloride, sulfate, bisulfate, monobasic, dibasic, and tribasic phosphates, mesylate, tosylate, and the like.
[0032] A "therapeutically effective amount" or dose of a compound or composition refers to that amount of the compound or composition that results in the reduction or inhibition of symptoms or prolongation of survival in a patient. The result may require multiple administrations of the compound or composition.
[0033] "Treatment" or "treating" refers to an approach to obtain beneficial or desired results, including clinical results. For purposes of the present invention, beneficial or desired results include, but are not limited to, one or more of the following: reducing one or more symptoms caused by a disease or disorder, reducing the extent of a disease or disorder, stabilizing a disease or disorder (e.g., preventing or delaying the worsening of a disease or disorder), delaying the onset or recurrence of a disease or disorder, delaying or slowing the progression of a disease or disorder, improving the condition of a disease or disorder, providing remission (partial or complete) of a disease or disorder, reducing the dose of one or more other drugs required to treat a disease or disorder, enhancing the effect of another drug used to treat a disease or disorder, slowing the progression of a disease or disorder, improving the quality of life, and / or prolonging the survival of a patient. "Treatment" also encompasses the alleviation of pathological consequences of a disease or disorder. The methods of the present invention contemplate any one or more of these aspects of treatment.
[0034] As used herein, "delaying" the onset of a disease means to prolong, prevent, delay, retard, stabilize, and / or postpone the onset of the disease, and / or to delay the progression of the disease once it has developed, or to change the underlying disease process and / or course. This delay can be of various lengths of time, depending on the history of the disease and / or individual being treated. As will be apparent to those skilled in the art, a sufficient or significant delay can actually encompass prevention, in that the individual does not develop clinical symptoms associated with the disease. A method of "delaying" the onset of a disease is a method that reduces the probability of disease development in a given time frame and / or reduces the extent of disease in a given time frame compared to not using the method, including stabilizing one or more symptoms resulting from the disease.
[0035] An individual "at risk" of developing a disease may or may not have detectable disease, and may or may not exhibit detectable disease prior to the treatment methods described herein. "At risk" indicates that an individual has one or more so-called risk factors, which are measurable parameters that correlate with the development of a disease. Individuals with one or more of these risk factors are more likely to develop a disease than individuals without these risk factor(s). These risk factors include, but are not limited to, age, sex, race, diet, previous medical history of disease, presence of precursor disease, and genetic (i.e., hereditary) considerations. In some embodiments, the compounds may be administered to subjects (including humans) at risk or with a family history of a disease or condition.
[0036] Dosage amounts of the compounds described herein are determined based on the free base of the compound.
[0037] Pharmaceutically acceptable compositions and formulations Pharmaceutically acceptable compositions or simply "pharmaceutical compositions" of any of the compounds detailed herein are encompassed by the present invention. Thus, the present invention includes pharmaceutical compositions comprising Compound 1 or a pharmaceutical acceptable salt thereof and a pharmaceutical acceptable carrier or excipient. In some embodiments, the pharmaceutical acceptable salt is an acid addition salt, such as a salt formed with an inorganic acid or an organic acid. The pharmaceutical composition according to the present invention may be in a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or in a form suitable for administration by inhalation.
[0038] The compounds detailed herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are detailed herein. Compositions comprising the compounds detailed herein or salts thereof, e.g., compositions of substantially pure compounds, are provided. In some embodiments, compositions containing the compounds detailed herein or salts thereof are in substantially pure form. In one variation, "substantially pure" contemplates a composition containing 35% or less impurities, impurities referring to compounds or salts thereof other than the compound that constitutes the majority of the composition. For example, a composition of a substantially pure compound contemplates a composition containing 35% or less impurities, impurities referring to compounds other than the compound or salts thereof. In one variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 25% or less impurities. In another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 20% or less impurities. In yet another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 10% or less impurities. In a further variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 5% or less impurities. In another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 3% or less impurities. In yet another variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 1% or less of impurities. In a further variation, a composition of a substantially pure compound or salt thereof is provided, the composition containing 0.5% or less of impurities. In yet another variation, a composition of a substantially pure compound means that the composition contains 15% or less, or preferably 10% or less, or more preferably 5% or less, or even more preferably 3% or less, and most preferably 1% or less of impurities, which may be different stereochemical forms of the compound.
[0039] In one variation, the compounds herein are synthetic compounds prepared for administration to an individual, such as a human. In another variation, compositions containing the compounds in substantially pure form are provided. In another variation, the invention encompasses pharmaceutical compositions comprising the compounds detailed herein and a pharma- ceutically acceptable carrier or excipient. In another variation, methods of administering the compounds are provided. The purified forms, pharmaceutical compositions, and methods of administering the compounds are suitable for any of the compounds detailed herein or forms thereof.
[0040] The compounds may be formulated for any available delivery route, including oral, mucosal (e.g., nasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., intramuscular, subcutaneous, or intravenous), topical, or transdermal delivery forms. The compounds may be formulated with suitable carriers to provide a delivery form, including, but not limited to, tablets, caplets, capsules (such as hard gelatin capsules or soft elastic gelatin capsules), cachets, troches, lozenges, gums, dispersions, suppositories, ointments, cataplasms (poultices), pastes, powders, dressings, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalers), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs.
[0041] The compounds described herein can be used to prepare formulations, such as pharmaceutical preparations, by combining the compound as an active ingredient with a pharma- ceutically acceptable carrier, such as those described above. Depending on the therapeutic form of the system (e.g., transdermal patch vs. oral tablet), the carrier can be in various forms. In addition, the pharmaceutical preparations can include preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants. Preparations containing the compounds can also contain other substances that have valuable therapeutic properties. Pharmaceutical preparations can be prepared by known pharmaceutical methods. Suitable formulations can be found, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21st ed. (2005), the contents of which are incorporated herein by reference.
[0042] The compounds described herein can be administered to individuals (e.g., humans) in the form of generally acceptable oral compositions, such as tablets, coated tablets, and hard or soft shell gel capsules, emulsions or suspensions. Examples of carriers that can be used to prepare such compositions include lactose, corn starch or its derivatives, talc, stearates or their salts, etc. Acceptable carriers for gel capsules with soft shells include, for example, vegetable oils, waxes, fats, semi-solids, and liquid polyols. In addition, pharmaceutical preparations can include preservatives, solubilizers, stabilizers, rewetting agents, emulsifiers, sweeteners, dyes, regulators, and salts for adjusting osmotic pressure, buffers, coating agents, or antioxidants.
[0043] Any of the compounds described herein can be formulated into a tablet in any of the dosage forms described herein.
[0044] The present disclosure further encompasses kits (e.g., pharmaceutical packages). The kits provided may include a pharmaceutical composition or compound described herein and a container (e.g., a drug bottle, an ampoule, a bottle, a syringe, and / or a subpackage, or other suitable container). In some embodiments, the kit includes a container that includes Compound 1 or a pharma-ceutically acceptable salt thereof.
[0045] In some embodiments, provided herein is a dosage form comprising a therapeutically effective amount of Compound 1, or a pharma- ceutically acceptable salt thereof.
[0046] Method and use In some aspects, the compounds and compositions described herein can be used to treat or prevent liver damage. In some embodiments, the method of treating or preventing liver damage in a patient includes administering to a patient a compound 1, a pharma- ceutical acceptable salt thereof.
[0047] Liver disorders include, but are not limited to, liver inflammation, fibrosis, and steatohepatitis. In some embodiments, liver disorders are selected from liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). In certain embodiments, liver disorders are selected from liver fibrosis, alcohol-induced fibrosis, NAFLD, and NASH. In one embodiment, liver disorders are NASH. In another embodiment, liver disorders are liver inflammation. In another embodiment, liver disorders are liver fibrosis. In another embodiment, liver disorders are alcohol-induced fibrosis. In another embodiment, liver disorders are NAFLD. In one embodiment, the therapeutic methods provided herein prevent or delay the progression of NAFLD to NASH. In one embodiment, the therapeutic methods provided herein prevent or delay the progression to NASH. NASH can progress to, for example, one or more of liver cirrhosis, liver cancer, and the like. In some embodiments, the liver disorder is NASH. In some embodiments, the patient has had a liver biopsy. In some embodiments, the method further comprises obtaining the results of the liver biopsy.
[0048] In some embodiments, a method of treating liver damage in a patient in need thereof, wherein the liver damage is selected from the group consisting of liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH).
[0049] Methods for treating or preventing liver damage in a patient (e.g., a human patient) in need thereof with Compound 1 or a pharma- ceutically acceptable salt thereof are provided, wherein the liver damage is selected from the group consisting of liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH).
[0050] Also provided herein is a method for preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) in a patient (e.g., a human patient) in need thereof, comprising administering an SSAO inhibitor (e.g., compound 1 or a pharmaceutically acceptable salt thereof). In some embodiments, the method comprises administering a therapeutically effective amount of compound 1. Also provided herein is a method for preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) in a patient (e.g., a human patient) in need thereof, comprising administering compound 1 or a pharmaceutically acceptable salt thereof.
[0051] In some embodiments, the present disclosure provides a method for treating liver disease in a patient in need of treatment with compound 1 or a pharma- ceutically acceptable salt thereof, wherein the SSAO inhibitor selectively inhibits SSAO.Thus, in some embodiments, MAO-A (monoamine oxidase A) is not inhibited.In some embodiments, MAO-B (monoamine oxidase B) is not inhibited.In some embodiments, MAO-A and MAO-B are not inhibited.
[0052] In some embodiments, the patient is a human. Obesity is highly correlated with NAFLD and NASH, but lean people can also be affected by NAFLD and NASH. Thus, in some embodiments, the patient is obese. In some embodiments, the patient is not obese. Obesity can also correlate with or cause other diseases, such as diabetes mellitus or cardiovascular disorders. Thus, in some embodiments, the patient also has diabetes mellitus and / or cardiovascular disorders. Without being bound by theory, it is believed that comorbidities such as obesity, diabetes mellitus, and cardiovascular disorders can make NAFLD and NASH more difficult to treat. Conversely, the only currently recognized way to address NAFLD and NASH is weight loss, which may have little or no effect on lean patients.
[0053] Although the risk of NAFLD and NASH increases with age, children can also suffer from NAFLD and NASH, with literature reports of cases occurring in children as young as 2 years of age (Schwimmer, et al., Pediatrics, 2006, 118:1388-1393). In some embodiments, the patient is 2-17 years of age, e.g., 2-10, 2-6, 2-4, 4-15, 4-8, 6-15, 6-10, 8-17, 8-15, 8-12, 10-17, or 13-17 years of age. In some embodiments, the patient is 18-64 years old, e.g., 18-55, 18-40, 18-30, 18-26, 18-21, 21-64, 21-55, 21-40, 21-30, 21-26, 26-64, 26-55, 26-40, 26-30, 30-64, 30-55, 30-40, 40-64, 40-55, or 55-64 years old. In some embodiments, the patient is 65 years old or older, e.g., 70 years old or older, 80 years old or older, or 90 years old or older.
[0054] Although NAFLD and NASH are common causes of liver transplantation, patients who have already undergone a liver transplant often develop recurrent NAFLD and / or NASH. Thus, in some embodiments, the patient has undergone a liver transplant.
[0055] In some embodiments, the patient is at risk of developing a side effect prior to administration in accordance with the methods provided herein, hi some embodiments, the side effect is a side effect affecting the kidneys, lungs, heart, and / or skin.
[0056] In some embodiments, the patient has previously undergone one or more therapies. In some embodiments, the liver damage progresses during treatment.
[0057] In some embodiments, the method does not include administering an antihistamine, an immunosuppressant, a steroid (such as a corticosteroid), rifampicin, an opioid antagonist, or a selective serotonin reuptake inhibitor (SSRI).
[0058] Also provided herein is a dosing regimen for administering compound 1 or a pharma- ceutically acceptable salt thereof. In some embodiments, a therapeutically effective amount of compound 1 or a pharma- ceutically acceptable salt thereof is a dose to achieve saturation of plasma SSAO. A dose to achieve saturation of plasma SSAO is a dose that reduces plasma SSAO activity by at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% compared to baseline levels. In some embodiments, a therapeutically effective amount of compound 1 or a pharma- ceutically acceptable salt thereof is a dose to achieve saturation of liver SSAO. Compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that is less than saturation of plasma SSAO and still be effective. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that achieves at least about 25% saturation of plasma SSAO targets. In other embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that achieves at least about 50% saturation of plasma SSAO targets. In other embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that achieves at least about 75% saturation of plasma SSAO targets.In other embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that achieves at least about 95% saturation of plasma SSAO targets.In other embodiments, compound 1 or a pharma- ceutically acceptable salt thereof may be administered at a dose that achieves about 100% saturation of plasma SSAO targets.
[0059] In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is administered as a pharmacokinetic (AUC) dose in a dose-dependent manner, as measured by the area under the steady-state plasma concentration curve from time 0 to infinity (AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞In some embodiments, the compound is administered daily to an individual at a dose that provides a steady-state plasma concentration-area under the curve, AUC 0-∞ is administered daily to an individual at a dose of about 10 ng*h / mL to about 20 ng*h / mL.
[0060] In some embodiments of the present disclosure, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient at a low dose of 1 mg or less once a day and still be able to sufficiently reduce amine oxidase activity and reduce lymphocyte adhesion and migration. For example, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 0.5 mg to about 25 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 1 mg to about 15 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 2 mg to about 10 mg once a day. In some embodiments, compound 1 or a pharma- ceutically acceptable salt thereof can be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 1 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 4 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 5 mg once a day. In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof may be orally administered to a patient with liver damage (e.g., NASH) at a dose of about 10 mg once a day.
[0061] In some embodiments, about 0.5 mg to about 50 mg of compound 1 or a pharma- ceutically acceptable salt thereof is administered to the individual. In a specific embodiment, the compound is orally administered to the patient once a day. In other embodiments, the compound is administered to the patient once every other day. In other embodiments, the compound is administered to the patient twice a week. In other embodiments, the compound is administered to the patient once a week. In some embodiments, about 1 mg to about 5 mg of the compound is administered to the individual. In some embodiments, about 1 mg to about 3 mg of the compound is administered to the individual. In some embodiments, about 5 mg to about 10 mg of the compound is administered to the individual. In some embodiments, about 10 mg to about 15 mg of the compound is administered to the individual. In some embodiments, about 15 mg to about 20 mg of the compound is administered to the individual. In some embodiments, about 20 mg to about 25 mg of the compound is administered to the individual. In some embodiments, about 25 mg to about 30 mg of the compound is administered to the individual. In some embodiments, about 30 mg to about 35 mg of the compound is administered to the individual. In some embodiments, about 35 mg to about 40 mg of the compound is administered to the individual. In some embodiments, about 40 mg to about 45 mg of the compound is administered to the individual. In some embodiments, about 45 mg to about 50 mg of the compound is administered to the individual. In some embodiments, about 0.5 mg of the compound is administered to the individual. In some embodiments, about 1 mg of the compound is administered to the individual. In some embodiments, about 2 mg of the compound is administered to the individual. In some embodiments, about 3 mg of the compound is administered to the individual. In some embodiments, about 4 mg of the compound is administered to the individual. In some embodiments, about 5 mg of the compound is administered to the individual. In some embodiments, about 6 mg of the compound is administered to the individual. In some embodiments, about 7 mg of the compound is administered to the individual. In some embodiments, about 8 mg of the compound is administered to the individual. In some embodiments, about 9 mg of the compound is administered to the individual. In some embodiments, about 10 mg of the compound is administered to the individual. In some embodiments, about 15 mg of the compound is administered to the individual.In some embodiments, about 20 mg of the compound is administered to the individual. In some embodiments, about 25 mg of the compound is administered to the individual. In some embodiments, about 30 mg of the compound is administered to the individual. In some embodiments, about 35 mg of the compound is administered to the individual. In some embodiments, about 40 mg of the compound is administered to the individual. In some embodiments, about 45 mg of the compound is administered to the individual. In some embodiments, about 50 mg of the compound is administered to the individual.
[0062] The treatment period may generally be one week or longer. In some embodiments, the treatment period is at least one week, two weeks, three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, one year, two years, three years, four years, or more. In some embodiments, the treatment period is about one week to about one month, about one month to about one year, about one year to about several years. In some embodiments, the treatment period is at least about one week, two weeks, three weeks, four weeks, five weeks, one month, two months, three months, four months, five months, six months, seven months, eight months, nine months, ten months, eleven months, twelve months, one year, two years, three years, four years, or more. In some embodiments, the treatment period is the remaining lifespan of the patient.
[0063] In some embodiments, the amount of Compound 1 or a pharma- ceutically acceptable salt thereof administered on day 1 of the treatment period is equal to or greater than the amount administered on all subsequent days of the treatment period. In some embodiments, the amount administered on day 1 of the treatment period is equal to the amount administered on all subsequent days of the treatment period.
[0064] Compound 1 or a pharma- ceutically acceptable salt thereof used according to the methods described herein may be administered to an individual at a dose once a day for a first period, and then the administration of the compound may be discontinued for a second period, and SSAO inhibitory activity is maintained during both the first and second periods. In some embodiments, the first and second periods are each a one week period. For example, provided herein is a 14 day treatment method for an individual, in which compound 1 or a pharma- ceutically acceptable salt thereof is administered to the individual at a dose once a day for the first 7 days, and the administration of the compound is discontinued for the next 7 days, and the SSAO inhibitory activity in the individual is maintained throughout the 14 day period. As another example, provided herein is a 4 week treatment method for an individual, in which compound 1 or a pharma- ceutically acceptable salt thereof is administered to the individual at a dose once a day for the first 2 weeks, and the administration of the compound is discontinued for the next 2 weeks, and the SSAO inhibitory activity in the individual is maintained throughout the 4 week period. In some embodiments, the daily dose is about 1 mg, about 3 mg, about 4 mg, about 5 mg, about 6 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, or about 40 mg.
[0065] In some embodiments, administering compound 1 or its pharma- ceutically acceptable salt reduces liver inflammation in an individual. Methods for assessing liver inflammation are known to those skilled in the art and may include histological analysis and assigning a histological score of lobular inflammation. Thus, in some embodiments, the therapeutic methods detailed herein include treating liver injury in an individual in need of treatment for liver injury, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), and it is understood that the treatment includes reducing lobular inflammation or histological markers associated with lobular inflammation.
[0066] In some embodiments, compound 1 or its pharma- ceutically acceptable salt reduces liver fibrosis in an individual. Methods for assessing liver fibrosis are known to those skilled in the art and may include histological analysis. Thus, in some embodiments, the treatment methods detailed herein include treating liver damage in an individual in need of treatment for liver damage, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and it is understood that treatment includes reducing fibrosis or histological markers associated with fibrosis.
[0067] In some embodiments, administering compound 1 or its pharma- ceutically acceptable salt reduces at least one of liver inflammation and fibrosis in an individual. In some embodiments, administering reduces liver inflammation and fibrosis in an individual. Thus, in some embodiments, the treatment methods detailed herein include treating liver injury in an individual in need of treatment, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), and it is understood that treating includes reducing at least one of lobular inflammation, fibrosis, or any of the histological markers described above.
[0068] In some embodiments, administering compound 1 or its pharma- ceutically acceptable salt reduces serum alanine aminotransferase in an individual.Thus, in some embodiments, the therapeutic methods detailed herein include treating liver damage in an individual in need of treatment, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), and it is understood that the treatment includes reducing serum alanine aminotransferase.
[0069] Also provided herein is Compound 1, or a pharma- ceutically acceptable salt thereof, for use in treating liver damage, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), in an individual in need of such treatment, using the methods described herein.
[0070] Also provided herein is the use of Compound 1, or a pharma- ceutically acceptable salt thereof, for the manufacture of a medicament for treating liver damage in an individual in need thereof, such as liver inflammation, liver fibrosis, alcohol-induced fibrosis, primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH), using the methods described herein.
[0071] combination The present disclosure further provides a combination of compound 1 or its pharmaceutically acceptable salt with other therapeutic agents used for the treatment of liver disease.In particular, the present disclosure provides a combination of compound 1 or its pharmaceutically acceptable salt with other therapeutic agents used for the treatment of NASH.As disclosed herein, compound 1 or its pharmaceutically acceptable salt is an attractive candidate for use in fixed-dose combination drugs for the treatment of NASH because of its low clinical dose.
[0072] In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered in combination with a farnesoid X receptor (FXR) agonist. In some embodiments, the FXR agonist is obeticholic acid. In some embodiments, the FXR agonist is cilofexor. In some embodiments, the FXR agonist is tropifexor. In some embodiments, the FXR agonist is EYP001 (Vonafexor, proposed by INN). In some embodiments, the FXR agonist is MET409 (Metacrine). In some embodiments, the FXR agonist is EDP-305 (by Enanta). In some embodiments, the FXR agonist is [ka] or a pharma- ceutically acceptable salt thereof.
[0073] In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered in combination with a peroxisome proliferator-activated receptor (PPAR) agonist. In some embodiments, the PPAR agonist is pioglitazone. In some embodiments, the PPAR agonist is rosiglitazone. In some embodiments, the PPAR agonist is elafibranor. In some embodiments, the PPAR agonist is saroglitazar. In some embodiments, the PPAR agonist is lanifibranor. In some embodiments, the PPAR agonist is seradelpar.
[0074] In some embodiments, Compound 1 or a pharma- ceutically acceptable salt thereof is administered in combination with a pan-caspase inhibitor. In some embodiments, the pan-caspase inhibitor is emricasan.
[0075] In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in combination with a galectin-3 inhibitor. In some embodiments, the galectin-3 inhibitor is belapectin.
[0076] In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in combination with an inhibitor of stearoyl Co-A desaturase 1. In some embodiments, the inhibitor of stearoyl Co-A desaturase 1 is aramchol.
[0077] In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in combination with a chemokine receptor type 2 and 5 (CCR2 / CCR5 chemokine) antagonist. In some embodiments, the CCR2 / CCR5 chemokine agonist is cenicriviroc.
[0078] In some embodiments, Compound 1, or a pharma- ceutically acceptable salt thereof, is administered in combination with an antioxidant. In some embodiments, the antioxidant is vitamin E.
[0079] Products and Kits The present disclosure further provides a product comprising the compound or salt thereof described herein, the composition described herein, or one or more unit doses described herein in suitable packaging.In certain embodiments, the product is for use in any of the methods described herein.Suitable packaging (e.g., containers) are known in the art and include, for example, vials, containers, ampoules, bottles, jars, flexible packaging, etc.The product may be further sterilized and / or sealed.
[0080] The present disclosure further provides a kit for carrying out the method of the present disclosure, comprising at least two compounds as described herein, or pharma- ceutically acceptable salts thereof, or a composition comprising the compounds as described herein, or pharma- ceutically acceptable salts thereof.The kit can use any of the compounds as described herein, or pharma- ceutically acceptable salts thereof.In some embodiments, the kit uses compound 1 as described herein, or pharma- ceutically acceptable salts thereof.The kit can be used for any one or more of the uses as described herein, and therefore can contain instructions for treatment as described herein.
[0081] The kit generally includes suitable packaging. The kit may include one or more containers that include any compound described herein or a pharma- ceutically acceptable salt thereof. Each component can be packaged in a separate container, or several components can be combined in one container that allows for cross-reactivity and shelf life. In some embodiments, the kit includes a container that includes Compound 1 or a pharma- ceutically acceptable salt thereof.
[0082] The kit may be a unit dosage form, bulk package (e.g., multiple dose package) or subunit dose. For example, a kit may be provided that contains a sufficient dose of the compound disclosed herein, or a pharma- ceutically acceptable salt thereof, and / or an additional pharma- ceutical active compound useful for the diseases detailed herein to provide effective treatment to an individual for an extended period of time, for example, 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or longer. The kit may also include a plurality of unit doses of the compound and instructions for use, and may be packaged in an amount sufficient for storage and use in a pharmacy (e.g., a hospital pharmacy and a compounding pharmacy).
[0083] The kit may optionally include a set of instructions, typically written instructions, although electronic storage media (e.g., magnetic diskettes or optical disks) containing instructions are acceptable relating to the use of the component(s) of the disclosed methods. The instructions included in the kit generally include information regarding the components and their administration to an individual. EXAMPLES
[0084] The treatments provided herein can be tested by administering a drug or drugs to a known mouse model and evaluating the results.The method of such testing can be adapted from known methods.See, for example, US Patent Publication No. 2015 / 0342943 (herein incorporated by reference).
[0085] Example 1 Background technology Semicarbazide-sensitive amine oxidase (SSAO) contributes to non-alcoholic steatohepatitis (NASH) by increasing oxidative stress through deamination of primary amines (e.g., methylamine, MMA) to aldehydes, ammonium, and H2O2, and by recruiting inflammatory cells to the liver, exacerbating liver inflammation and injury. SSAO levels are elevated in NASH and correlate with fibrosis stage. Compound 1 is a selective covalent SSAO inhibitor that reduces liver inflammation and fibrosis in a rat model of NASH. A single-dose escalation study of Compound 1 was performed.
[0086] method Four groups of eight healthy participants were randomized to receive capsules of Compound 1 or matching placebo in a 3:1 ratio. Plasma levels of Compound 1 and PD biomarkers were determined before and at various time points after dosing. SSAO inhibition was determined by measuring the relative decrease in plasma H2O2 generation after addition of an exogenous substrate (benzylamine). Endogenous methylamine (MMA) levels, which are predicted to increase upon SSAO inhibition, were measured in plasma. Safety was evaluated for 7 (± 3) days after dosing.
[0087] Plasma samples for Compound 1 concentration and SSAO activity measurements were collected at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48 (SSAO activity only), and 168 (SSAO activity only) hours after a single dose of test drug (placebo or compound). Plasma PK parameters were determined by non-compartmental analysis. SSAO activity was assessed by measuring hydrogen peroxide (H2O2) generation levels in plasma samples from placebo and active Compound 1 recipients. Percent changes in total amine oxidase activity were determined compared to corresponding pre-dose (baseline) samples.
[0088] SSAO-specific amine oxidase levels in plasma were determined using a kinetic assay essentially as previously described (Schilter et al.). Endogenous monoamine oxidases A and B were inhibited by adding pargyline to plasma samples prior to measuring H2O2 production levels in placebo and active recipients. Maximal inhibition was defined using pre-dose (baseline) samples additionally treated with high doses of Compound 1, and the percent change in SSAO-specific activity was calculated compared to baseline samples.
[0089] result Thirty-two healthy human participants (100% male, 63% black, 19% Asian, 13% white) were enrolled and administered a single oral dose of compound 1 (1, 3, 6, and 10 mg, n=6 each) or placebo (n=2). Plasma PK exposure of compound 1 increased in a greater than dose-proportional manner between the 3 mg and 10 mg dose levels. The mean half-life of compound 1 ranged from 1 to 3 hours. Four hours after dosing, there was near complete inhibition of plasma SSAO activity in all dose cohorts, with continued suppression detectable for up to 1 week after a single dose of compound 1. Maximum plasma MMA levels were increased with compound 1. No clinically relevant adverse events or laboratory abnormalities were reported.
[0090] As shown in Table 1, doses of 1, 3, 6, and 10 mg of Compound 1 were all well tolerated. [Table 1]
[0091] A single dose of the tosylate salt of compound 1 was rapidly cleared from plasma and demonstrated greater than dose-proportional plasma PK from 3 to 10 mg.
[0092] As shown in Figure 1A and Figure 1B, a single dose of Compound 1 rapidly and potently reduced plasma amine oxidase activity in all subjects. Near-complete inhibition of SSAO-specific activity was observed 4 hours after dosing (Figure 1A and Figure 1B). Inhibition of plasma SSAO amine oxidase activity and a dose-dependent increase in plasma MMA persisted for up to 1 week after a single dose of Compound 1, suggesting strong covalent target engagement and supporting once-daily dosing despite the short plasma half-life (Figure 1A and Figure 1B).
[0093] Concentration of Compound 1 against SSAO (C max ) was the IC of MAO-A and MAO-B at all dose levels. 50 The concentration was >800-fold lower than that in the control group (Fig. 1C, Table 2). [Table 2]
[0094] A dose-dependent increase in methylamines was observed, indicating potent plasma SSAO target engagement across the dose range (Figure 1D).
[0095] conclusion Compound 1 was safe and well tolerated in healthy subjects administered a single oral dose ranging from 1 mg to 10 mg. Compound 1 inhibited SSAO activity for up to 7 days after a single dose. This suggests that Compound 1 may be effective in treating liver disease or disorders by selectively inhibiting SSAO. It may also show SSAO activity for 7 days after a single dose, suggesting that daily administration for 1 week may exert a therapeutic effect for 2 weeks.
[0096] Example 2 A multiple-dose ascending-dose study of Compound 1 was conducted. Three groups of eight healthy participants were randomized to receive multiple once-daily (QD) doses of Compound 1 or matching placebo in a 3:1 ratio for 7 days (1 mg and 4 mg) or 14 days (10 mg). Plasma levels of Compound 1 and PD biomarkers (plasma amine oxidase activity and methylamine levels) were determined pre- and at various time points post-dose. Safety, including specifically clinical laboratory values, vital signs, and electrocardiograms, was evaluated for up to 14 days after the last dose and was unremarkable across subjects. All adverse events were judged to be mild (grade 1), with the exception of one moderate (grade 2) adverse event in the placebo treatment group. No subjects discontinued the study due to adverse events (see Table 3).
[0097] Increases in plasma PK exposure of compound 1 were greater than dose proportional between dose groups on day 1, with significant accumulation observed at each dose level after multiple QD dosing. The rate of accumulation between the first and last day of dosing decreased as dose increased. Steady state was achieved after 7 days in the highest dose cohort (10 mg). The half-life of compound 1 increased with dose, consistent with saturable target-mediated clearance (see Figures 2A and 2B, Table 4).
[0098] On day 1, we found a near-complete inhibition of plasma SSAO activity in all dosing cohorts (Fig. 3A), which resulted in an increase in methylamine, an endogenous substrate of SSAO (Fig. 3B). Plasma methylamine concentrations increased in a dose-proportional manner (Fig. 3B). After multiple dosing, a further increase in plasma methylamine was observed on the last day of dosing with Compound 1 (Fig. 3C). There were plasma amine oxidases (e.g., MAO-A, MAO-B) that were not inhibited by Compound 1, so inhibition of total amine oxidase was incomplete (Fig. 3D,E).
[0099] Compound 1 was safe and well tolerated when administered in healthy subjects at doses up to 10 mg QD for 14 days. Steady-state levels of compound 1 were achieved after 7 days of dosing, supporting the QD dosing regimen. Near-complete inhibition of plasma SSAO amine oxidase activity and dose-dependent increases in plasma methylamines persisted for up to 2 weeks after dosing was discontinued, suggesting that compound 1 administered daily for 2 weeks may exert a therapeutic effect for up to 2 weeks after dosing was discontinued. [Table 3] [Table 4]
[0100] Example 3 A multicenter, randomized, double-blind, dose-ranging, placebo-controlled clinical trial will be conducted to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of oral Compound 1 in patients with suspected non-cirrhotic nonalcoholic steatohepatitis (NASH). The total duration of study participation will be approximately 22 weeks, consisting of a 6-week screening period, a 12-week treatment period, and a 4-week follow-up period.
[0101] Approximately 80 adult patients with clinically or histologically diagnosed, probable NASH without cirrhosis who meet the study's eligibility criteria will be enrolled and randomized to the three dose groups or placebo in an overall 2:1 ratio across the two parts of the study. Eligibility criteria include overweight or obesity, presence of NASH by clinical diagnosis or biopsy, ALT ≥ 43U / L (men) or ≥ 28U / L (women), and MRI-cT1 hepatitis > 800ms.
[0102] The first part of this study will evaluate 10 mg of Compound 1, the highest dose studied in Example 2. In Example 2, this dose inhibited plasma VAP-1 / SSAO-specific amine oxidase activity in healthy participants by >90%. Since NASH patients are expected to have higher baseline levels of VAP-1, the PD effect of Compound 1 in NASH patients may differ from healthy participants. Based on the safety and PK evaluation at the 10 mg dose, a higher dose of up to 20 mg may be enrolled, and based on the strong PD effect of Compound 1 observed on plasma VAP-1 / SSAO activity in the 10 mg cohort, a lower dose of 4 mg may be enrolled. This will minimize the number of patients exposed until the PK and PD effects of Compound 1 are confirmed in the first part of the study.
[0103] In the first part, approximately 30 patients will receive 10 mg of Compound 1 (n=20) or matching placebo (n=10) orally once daily for 12 weeks. Approximately 12 randomized patients will participate in focused PK and PD collections at week 0 / day 1, week 6, and week 12 after the last dose of study drug. Approximately 8 patients in the Compound 1 group and 4 patients in the placebo group will be randomized to the PK / PD substudy. Patients not participating in the PK / PD substudy will only undergo trough PK / PD sampling.
[0104] An interim analysis will be performed once all patients in the first part have completed the Week 6 evaluation. Interim PK and PD data will be evaluated. Blinded safety data will also be considered. If potent VAP-1 / SSAO inhibition is observed and PK from the first part suggests that potent VAP-1 / SSAO inhibition may be achieved at lower doses, enrollment in the second part with 4 mg Compound 1 may begin. If safety data indicate that 10 mg Compound 1 is generally safe and well tolerated, and target exposures for doses up to 20 mg are expected to be within AUC 10 mg based on PK from the first part. 0-24hrAbout 5400ng·hr / mL and C max If the mean serum IL-1 levels are expected to fall below the upper limit of 768 ng / mL, enrollment into the second part, which will involve administration of Compound 1 at doses up to 20 mg, may begin.
[0105] In the second part, approximately 50 patients will receive 4 mg of Compound 1 (n=20) and / or up to 20 mg of Compound 1 (n=20) or matching placebo (n=10) orally once daily for 12 weeks. Approximately 15 randomized patients will participate in focused PK and PD collections at week 0 / day 1, week 6, and week 12 after the last dose of study drug. Approximately 6 patients at each dose level of Compound 1 and approximately 3 patients in the placebo group will be randomized to the PK / PD substudy. Patients not participating in the PK / PD substudy will only undergo trough PK / PD sampling.
[0106] PK / PD substudy and trough PK / PD sampling Plasma samples will be collected to measure the concentration of study drug and metabolites in plasma. Urine samples will be collected to measure the concentration of study drug and metabolites in urine. Patients not participating in the PK / PD substudy will only have trough PK sampling performed. Blood will also be collected for NASH / fibrosis markers (CK-18 (M30 and M65), PIIINP, TIMP-1, HA, PRO-C3, and C3M) and inflammatory markers (hs-CRP, IL-6, ICAM-1, and VCAM-1). Exploratory fibrosis scores for FIB-4, enhanced liver fibrosis (ELF), and NAFLD may also be calculated. PRO-C3 / C3M ratios may be calculated. Patients will be monitored for adverse events.
[0107] Plasma and urine samples will be collected pre-dose from all patients on days 1, 2, 15, 29, 43, 57, and 85. For patients in the PK / PD substudy, plasma samples will be collected 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after dosing on days 1 (week 0), 43 (week 6), and 85 (week 12), and total urine collections will be performed 0-8 hours after dosing. Samples will be collected on days 2 (week 0), 44 (week 6), and 96 (week 12) (24 hours after dosing). Samples will be collected on days 87 and 88 (48 and 72 hours after dosing on week 12). Markers including ALT, AST, ALP, and total bilirubin will be monitored.
[0108] Example 4 method The first part of the two-part trial was a double-blind, placebo-controlled study in 30 adults with a noncirrhotic NASH phenotype who were evaluated for 12 weeks with 10 mg of compound 1 administered once daily (QD), followed by a post-treatment evaluation at week 16 (Figure 4). Safety assessed by adverse events (AEs) and laboratory tests was the primary endpoint of the interim analysis of the first part, and percent change from baseline (BL) in plasma VAP-1 activity was the secondary endpoint. Exploratory imaging and blood-based biomarkers of liver inflammation and fibrosis were also evaluated. Analysis of change from baseline (or percent change) used an ANCOVA model with treatment group and randomization stratum as fixed effects and change from baseline (or percent change) as the dependent variable, including baseline as a covariate.
[0109] result Patient demographics and baseline characteristics in the placebo and treatment groups were similar overall (Figure 5). Nearly all patients (28 of 30, 95% Compound 1, 90% placebo) completed the first part (Figure 6). Compound 1 (10 mg) was well tolerated with AE rates similar to placebo (Figure 7). All AEs were mild or moderate, and no serious AEs or trends of AEs, or laboratory abnormalities were reported. No significant changes in cT1 were observed from baseline to end of treatment (Figure 9). Compound 1 (10 mg) inhibited plasma VAP-1 activity by >98% in most subjects by week 2, with inhibitory effects sustained through week 12 (Figure 10). There were no statistically significant differences in changes from BL cT1, liver fat content, liver enzymes, or cytokeratin-18 between placebo and Compound 1 10 mg. At week 12, significant differences from placebo were observed in the cell adhesion marker VCAM-1 and the liver fibrosis marker tissue inhibitor of metalloproteinase 1 (TIMP-1) (Figures 8A, 8B, 11, and 12). For cell adhesion markers including VCAM-1 and ICAM-1, at week 12, VCAM-1 decreased by a mean (±SE) of 24.327 (20.5850) μg / L in the Compound 1 group and increased by a mean (±SE) of 63.450 (31.6861) in the placebo group compared to BL (p=0.0245). At week 8, ICAM-1 decreased by a mean (±SE) of 34.85 (56.03) μg / L in the Compound 1 group and increased by a mean (±SE) of 7.46 (46.97) in the placebo group compared to BL (p=0.0313). At week 12, tissue TIMP-1 decreased by a mean (±SE) of 29.58 (9.26) ng / mL in the compound 1 group and increased by a mean (±SE) of 13.56 (14.22) ng / mL in the placebo group compared with BL (p<0.05).
[0110] conclusion Compound 1 was well tolerated with a safety profile similar to placebo in patients with baseline multiparametric MRI and LS values indicating NASH with at least stage 2 fibrosis. Compound 1 (10 mg) produced near complete inhibition of plasma VAP-1 activity, reduced levels of the liver fibrosis marker TIMP-1, and statistically significant reductions in the cell adhesion biomarkers ICAM-1 (week 8) and VCAM-1 (week 12) compared with placebo. After 12 weeks of treatment, no statistically significant differences were observed between compound 1 and placebo for other markers of liver inflammation and injury. Overall, these data support further evaluation of the safety and activity of 20 mg compound 1 in the second part of the ongoing study in patients with NASH.
[0111] All publications, including patents, patent applications, and scientific articles, mentioned in this specification are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, including a patent, patent application, or scientific article, was specifically and individually indicated to be incorporated by reference.
[0112] Although the foregoing invention has been described in some detail by way of illustration and example for clarity of understanding, it will be apparent to those skilled in the art that certain minor changes and modifications may be implemented in light of the above teachings. Accordingly, the descriptions and examples should not be construed as limiting the scope of the invention.
Claims
1. A method of treating non-alcoholic steatohepatitis (NASH) in a patient in need thereof, comprising administering to said patient a compound of the formula: [Formula 1] or a pharma- ceutically acceptable salt thereof orally administered once daily at a dose of about 0.5 mg to about 25 mg.
2. 10. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 1 mg to about 15 mg.
3. 10. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 2 mg to about 10 mg.
4. 10. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 4 mg to about 10 mg.
5. 13. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 1 mg.
6. 13. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 4 mg.
7. 13. The method of claim 1, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 10 mg.
8. A method of treating NASH in a patient in need thereof, comprising administering to said patient a compound of the formula: [Case 2] or a pharma- ceutical acceptable salt thereof, at a dose such that when the plasma concentration of the compound reaches steady state, the methylamine concentration in the plasma is at least about 25 ng / mL.
9. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose that results in a methylamine concentration in the plasma of at least about 50 ng / mL when the plasma concentration of the compound reaches steady state.
10. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose that results in a methylamine concentration in the plasma of at least about 100 ng / mL when the plasma concentration of the compound reaches steady state.
11. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose that results in a methylamine concentration in the plasma of at least about 300 ng / mL when the plasma concentration of the compound reaches steady state.
12. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose that results in a methylamine concentration in the plasma of about 25 ng / mL to about 400 ng / mL when the plasma concentration of the compound reaches steady state.
13. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose that results in a methylamine concentration in the plasma of about 50 ng / mL to about 350 ng / mL when the plasma concentration of the compound reaches steady state.
14. 9. The method of claim 8, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose such that when the plasma concentration of the compound reaches steady state, the methylamine concentration in the plasma is from about 100 ng / mL to about 300 ng / mL.
15. The method of any one of claims 8 to 14, wherein the compound or a pharma- ceutically acceptable salt thereof is administered orally.
16. The method according to any one of claims 8 to 14, wherein the compound or a pharma- ceutically acceptable salt thereof is administered parenterally.
17. A method of treating NASH in a patient in need thereof, comprising administering to said patient a compound of the formula: [C3] or a pharma- ceutically acceptable salt thereof, to said patient, and measuring the steady-state area under the curve from time 0 to infinity (AUC 0-∞ ) at a dose of about 100 ng*h / mL to about 1,000 ng*h / mL.
18. The compound or a pharma- ceutically acceptable salt thereof is administered at a steady-state AUC 0-∞ The method of claim 17, wherein the amount of the IL-10 is about 100 ng*h / mL to about 700 ng*h / mL.
19. The compound or a pharma- ceutically acceptable salt thereof is administered at a steady-state AUC 0-∞ The method of claim 17, wherein the amount of the IL-10 receptor agonist is about 500 ng*h / mL to about 1,000 ng*h / mL.
20. The compound or a pharma- ceutically acceptable salt thereof is administered at a steady-state AUC 0-∞ The method of claim 17, wherein the amount of the IL-10 is about 500 ng*h / mL to about 700 ng*h / mL.
21. The method of any one of claims 17 to 20, wherein the compound or a pharma- ceutically acceptable salt thereof is administered orally.
22. The method of any one of claims 17 to 20, wherein the compound or a pharma- ceutically acceptable salt thereof is administered parenterally.
23. A method of treating NASH in a patient in need thereof, comprising administering to said patient a compound of the formula: [C4] or a pharmaceutically acceptable salt thereof to said patient, wherein said compound or a pharmaceutically acceptable salt thereof is administered once every other day.
24. A method of treating NASH in a patient in need thereof, comprising administering to said patient a compound of the formula: [C5] or a pharmaceutically acceptable salt thereof to said patient, wherein said compound or a pharmaceutically acceptable salt thereof is administered twice weekly.
25. A method of treating NASH in a patient in need thereof, comprising administering to said patient a compound of the formula: [C6] or a pharma- ceutically acceptable salt thereof to said patient, wherein said compound or a pharma- ceutically acceptable salt thereof is administered once a week.
26. 26. The method of any one of claims 23 to 25, wherein the compound or a pharma- ceutically acceptable salt thereof is administered in a dose of about 0.5 mg to about 25 mg.
27. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered in a dose of about 1 mg to about 15 mg.
28. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered in a dose of about 2 mg to about 10 mg.
29. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered in a dose of about 4 mg to about 10 mg.
30. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose of about 1 mg.
31. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered at a dose of about 4 mg.
32. 27. The method of claim 26, wherein the compound or a pharma- ceutically acceptable salt thereof is administered once daily at a dose of about 10 mg.
33. The method of any one of claims 23 to 32, wherein the compound or a pharma- ceutically acceptable salt thereof is administered orally.
34. The method of any one of claims 23 to 32, wherein the compound or a pharma- ceutically acceptable salt thereof is administered parenterally.
35. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a farnesoid X receptor (FXR) agonist.
36. The FXR agonist is [C7] or a pharma- ceutically acceptable salt thereof.
37. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a peroxisome proliferator-activated receptor (PPAR) agonist.
38. 38. The method of claim 37, wherein the PPAR agonist is pioglitazone, rosiglitazone, elafibranor, saroglitazar, lanifibranor, or seradelpar.
39. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a pan-caspase inhibitor.
40. 40. The method of claim 39, wherein the pan-caspase inhibitor is emricasan.
41. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a galectin-3 inhibitor.
42. 42. The method of claim 41, wherein the galectin-3 inhibitor is belapectin.
43. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a stearoyl Co-A desaturase 1 inhibitor.
44. 44. The method of claim 43, wherein the stearoyl Co-A desaturase 1 inhibitor is aramchol.
45. The method of any one of claims 1 to 34, wherein the compound is administered in combination with a chemokine receptor type 2 and 5 (CCR2 / CCR5 chemokine) antagonist.
46. 46. The method of claim 45, wherein the CCR2 / CCR5 chemokine agonist is cenicriviroc.
47. The method of any one of claims 1 to 34, wherein the compound is administered in combination with an antioxidant.
48. 48. The method of claim 47, wherein the antioxidant is Vitamin E.
